DTU
DTU

Welcome to the Diabetes Trials Unit

The Diabetes Trials Unit (DTU) is a fully registered UK Clinical Research Collaboration Clinical Trials Unit, specialising in performing local, national and multinational clinical trials related to the treatment and management of cardiometabolic and related disorders.

[More about the DTU]

Get involved

Patients and the public can get involved in research in a number of ways, including as a participant in a trial, by determining research priorities, or by contributing to the design or dissemination of research. Read more about getting involved here

Watch our video to hear the experience of previous trial participants and the views of our research staff.

Participants in our trials may be patients, with diabetes or other medical conditions, or healthy volunteers. Please visit our Trials page if you are interested getting involved to see our trials that are recruiting currently.

News

Rajna Golubic winner of the Turner-Warwick lecturer scheme 2021

07-Jan-2022
News Image

The Royal College of Physicians has awarded Dr Rajna Golubic, an academic clinical lecturer in the DTU, as the overall national winner of the 2021 Turner-Warwick lecturer scheme for her lecture entitled “Novel treatments to improve metabolic health in obesity and type 2 diabetes: the effects of cotadutide”. The lecture included the results of a mechanistic study conducted as a collaboration between the University of Cambridge and AstraZeneca....

[Read more...]

Impact of Semaglutide in Amyloid Positivity trial

10-Dec-2021
News Image

New Clinical Trial to Test Drug for Diabetes in Reducing Risk of Alzheimer's Dementia

- Lack of effective treatments for Alzheimer's dementia is one of key challenges to modern medicine and society

A new study led through a collaboration between the Diabetes Trials Unit and the Department of Psychiatry at the University of Oxford, and the global healthcare company, Novo Nordisk, will examine whether semaglutide, a tablet used to treat diabetes, can change the course of the earliest changes that happen in the brains of people at risk of developing Alzheimer's dementia.

The Impact of Semaglutide in Amyloid Positivity (ISAP) trial will recruit 88 volunteers currently living without dementia from five UK clinical sites in: Oxford, Imperial College London, University College London, Exeter, and Bristol....

[Read more...]

Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90)

26-Jul-2021
News Image

Computer simulation models, such as the UKPDS Outcomes model 2 (UKPDS-OM2), allow users to predict disease progression, health outcomes and costs in individuals with type 2 diabetes.
Data from 5,102 UKPDS participants from the 20-year trial and 4,031 survivors with 10 years post-trial follow-up were used to derive time path equations for 13 clinical risk factors: HbA1c, systolic blood pressure, LDL-cholesterol, HDL-cholesterol, BMI, micro- or macro-albuminuria, creatinine, heart rate, white blood cell count, haemoglobin, eGFR, atrial fibrillation and peripheral vascular disease....

[Read more...]


[News archive]